Treatment Options in Late-line Colorectal Cancers

Created using ChatSlide

This conference session provides a concise, practice-focused update on late-line metastatic colorectal cancer, emphasizing fitness-based treatment, biomarker-driven sequencing, and access-aware decision-making. It reviews current evidence for oral agents, FTD/TPI plus bevacizumab, immunotherapy in MSI-H disease, EGFR rechallenge guided by ctDNA, and targeted options for KRAS G12C, BRAF V600E, HER2, NTRK, and rare drivers. Through trial data, negative lessons, and case-based scenarios,...